FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Autoimmune topics
Autoimmune
Immune Disease
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Transplant
Immune Disorder
Autoimmune Disorder
Autoimmune Disorders
Infectious
Infectious Disease
Inflammatory Disease
Type 1 Diabetes
Proliferative Disorder
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Autoimmune patents



      
           
This page is updated frequently with new Autoimmune-related patent applications. Subscribe to the Autoimmune RSS feed to automatically get the update: related Autoimmune RSS feeds. RSS updates for this page: Autoimmune RSS RSS


Date/App# patent app List of recent Autoimmune-related patents
07/17/14
20140200273
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140200272
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140200245
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
07/17/14
20140200200
 Antagonists of cb1 receptor patent thumbnailAntagonists of cb1 receptor
The invention relates to an antagonist of cb1 receptor for use in the treatment of a pathologic condition or disorder selected from the group consisting of bladder and gastrointestinal disorders; inflammatory diseases; cardiovascular diseases; nephropathies; glaucoma; spasticity; cancer; osteoporosis; metabolic disorders; obesity; addiction, dependence, abuse and relapse related disorders; psychiatric and neurological disorders; neurodegenerative disorders; autoimmune hepatitis and encephalitis; pain; reproductive disorders and skin inflammatory and fibrotic diseases.. .
07/17/14
20140199393
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199392
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199390
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199388
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199387
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199386
 Controlled release pharmaceutical compositions comprising a fumaric acid ester patent thumbnailControlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/17/14
20140199379
Compositions having means for targeting at least one antigen to dendritic cells
A composition that can be used as a vaccine containing means for targeting at least one antigen to dendritic cells and as adjuvants a granulocyte macrophage colony stimulating factor and a cpg oligodeoxynucleotide and/or a cpg-like oligodeoxynucleotide. This composition can used to treat cancers, infectious diseases caused by bacterial, viral, fungal, parasitic or protozoan infections, allergies and/or autoimmune diseases..
07/17/14
20140199328
Interferon alpha antibodies and their uses
The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (ifn) alpha subtypes but do not substantially inhibit the biological activity of ifn alpha 21 or the biological activity of either ifn beta or ifn omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided.
07/17/14
20140199299
Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists
This invention relates generally to compositions that contain multiple modulating agents, e.g., multiple modulating agents that target cd3 on t cells and neutralize one or more biological activities of interleukin-6 (il-6), such as cd3 modulators including anti-cd3 antibodies and anti-il-6 antagonists including anti-il-6 antibodies, anti-il-6r antagonists including anti-il-6r antibodies, and/or anti-il-6/il-6r complex antagonists including anti-il-6/il-6r binding antibodies, and methods of using these compositions in the treatment, amelioration and/or prevention of relapse of an autoimmune disease.. .
07/10/14
20140195216
Computational design of ideotypically modulated pharmacoeffectors for selective cell treatment
In system and method embodiments, an embodiment includes the collection, input, and organization of target nucleotide source or sources; the identification of potential target sequences for ideotypically modulated pharmacoeffectors (imp); the exclusion, prioritization, or deprioritization of target sequences on the basis of undesirable binding for ideotypically modulated pharmacoeffectors (imp); and/or the design of targeting sequences on the basis of reverse complementarity or sequence complementarity. Imps are designed for optimal use in respective applications, including cancers, autoimmune diseases, infectious diseases, cellular diseases, and other applications..
07/10/14
20140194612
Immunosuppression compound and treatment method
A method and compound for suppressing an immune response in a mammalian subject, for the treatment or prevention of an autoimmune condition or transplantation rejection are disclosed. The compound is an antisense oligonucleotide analog compound having a targeting sequence complementary to a preprocessed ctla-4 mrna region identified by seq id no: 22 in seq id no: 1, spanning the splice junction between intron 1 and exon 2 of the preprocessed mrna of the subject.
07/10/14
20140194599
Anti-human interleukin-20 antibodies
Anti-human il20 monoclonal antibodies that can reduce il20 mediated activation of both il20r1/il20r2 and il22r1/il20r2 receptor complexes in one or more species, including humans, are described, as well as antigen-binding molecules such as, e.g., antigen-binding antibody fragments, antibody derivatives, and multi-specific molecules designed or derived from such antibodies, and methods or producing such antibodies or other antigen-binding molecules. Such antibodies or other antigen-binding molecules can be used for treating various diseases and disorders, including autoimmune or inflammatory diseases or disorders..
07/10/14
20140194517
Treatment of graft-versus-host disease disorders using rar antagonists
The present specification provides rar antagonist compounds, compositions comprising such rar antagonists, and methods using such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection as well as use of such rar antagonists to manufacture a medicament and use of such compounds and compositions to treat an autoimmune disorder, inflammation associated with an autoimmune disorder and/or a transplant rejection.. .
07/10/14
20140194343
Ctrp6 which can be used as therapeutic and prophylactic agent for autoimmune diseases
[solution] a pharmaceutical composition containing ctrp6 for the prevention or treatment of autoimmune disease. Ideally, a pharmaceutical composition for the prevention or treatment of inflammation associated with autoimmune disease, for example, rheumatoid arthritis or type 1 diabetes, is provided..
07/10/14
20140193495
Controlled release pharmaceutical compositions comprising a fumaric acid ester
The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g.
07/10/14
20140193408
Soluble proteins for use as therapeutics
The present invention relates to improved binding proteins, for use as a medicament, in particular for the prevention or treatment of autoimmune and inflammatory disorders, for example allergic asthma and inflammatory bowel diseases. The invention more specifically relates to a soluble protein, comprising a complex of two heterodimers, wherein each heterodimer essentially consists of: (i) a first single chain polypeptide comprising: (a) an antibody heavy chain sequence having vh, ch1, ch2, and ch3 regions; and (b) a monovalent region of a mammalian binding molecule fused to the vh region; and (ii) a second single chain polypeptide comprising: (c) an antibody light chain sequence having a vl and cl region; and (d) a monovalent region of a mammalian binding molecule fused to the vl region; characterised in that each pair of vh and vl cdr sequences has specificity for an antigen, such that the total valency of said soluble protein is six.
07/10/14
20140193396
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
The invention provides immune regulatory oligonucleotides (iro) as antagonist of tlrs and methods of use thereof. These iros have unique sequences that inhibit tlr-mediated signaling in response to a tlr ligand or tlr agonist.
07/10/14
20140193337
18f-saccharide-folates
The present invention is directed towards new 18f-folate radiopharmaceuticals, wherein the 18f isotope is linked via a prosthetic group, more specifically via a prosthetic group having a saccharide group, such as a cyclic mono- or oligosaccharide, preferably based on a pyranoside or furanoside, which is covalently linked to the glutamate portion of a folate or derivative thereof, a method of their preparation, as well as their use in diagnosis and monitoring of cancer and inflammatory and autoimmune diseases and therapy thereof.. .
07/03/14
20140187565
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
07/03/14
20140187564
Inhibitors of bruton's tyrosine kinase
Disclosed herein are compounds that form covalent bonds with bruton's tyrosine kinase (btk). Also described are irreversible inhibitors of btk.
07/03/14
20140187534
Nitrogen-containing spirocyclic compounds and pharmaceutical uses thereof
Wherein each symbol has the same meaning as defined herein, or a pharmaceutically acceptable salt thereof, or a solvate thereof, and a pharmaceutical use of the same in treating organ transplant rejection, graft versus host reaction after transplantation, autoimmune disease, allergic disease and chronic myeloproliferative disease.. .
07/03/14
20140187485
Novel receptor nucleic acids and polypeptides
Disclosed are nucleic acids encoding baff-r polypeptides, as well as antibodies to baff-r polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided..
07/03/14
20140186947
Activation and expansion of t-cells using an engineered multivalent signaling platform as a research tool
Provided are a system and methods for selectively inducing expansion of a population of t cells in the absence of exogenous growth factors, such as lymphokines, and accessory cells for research purposes. The cell based expansion system and methods permit the long-term growth of ctls, preferably human ctls.
07/03/14
20140186848
Quantification of adaptive immune cell genomes in a complex mixture of cells
Compositions and methods are described for highly sensitive quantification of the relative representation of dna from adaptive immune cells (e.g., t and/or b lymphocytes) in dna extracted from complex mixtures of cells that include cells which are not adaptive immune cells. Included are methods for determining the relative presence in a tumor of tumor infiltrating lymphocytes (til), the relative presence of lymphocytes infiltrating a somatic tissue that is the target of an autoimmune disease, and the relative presence of lymphocytes infiltrating a transplanted organ..
07/03/14
20140186400
Methods and compositions for treating autoimmune diseases
The invention features methods for increasing or maintaining the number of functional cells of a predetermined type, for example, insulin producing cells of the pancreas, blood cells, spleen cells, brain cells, heart cells, vascular tissue cells, cells of the bile duct, or skin cells, in a mammal (e.g., a human patient) that has injured or damaged cells of the predetermined type.. .
07/03/14
20140186374
Manipulation of regulatory t cell and dc function by targeting neuritin gene using antibodies, agonists and antagonists
We demonstrate herein that neuritin controls the homeostasis of regulatory t cells in an antigen dependent manner. Based on this discovery, we describe herein the application of neuritin as a therapeutic agent to manipulate antigen specific regulatory t cells in various disease settings is described.
07/03/14
20140186372
Compositions targeting pkc-theta and uses and methods of treating pkc-theta pathologies, adverse immune responses and diseases
The invention relates to compositions, methods and uses of inhibitors of binding between pkcθ and cd28, and modulating an undesirable or aberrant immune response, disorder or disease, an inflammatory response, disorder or disease, inflammation or an autoimmune response, disorder or disease. Compositions include inhibitors of binding between pkcθ and cd28, which include, among others, pkcθ, cd28 and lck sequences, subsequences, variants and modified forms, and polymorphisms..


Popular terms: [SEARCH]

Autoimmune topics: Autoimmune, Immune Disease, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Transplant, Immune Disorder, Autoimmune Disorder, Autoimmune Disorders, Infectious, Infectious Disease, Inflammatory Disease, Type 1 Diabetes, Proliferative Disorder, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Autoimmune for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Autoimmune with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         


FreshNews promo



0.1797

4006

2 - 1 - 78